Real-world effectiveness and safety of TACE combined with lenvatinib plus immune checkpoint inhibitors in patients with BCLC-B stage hepatocellular carcinoma
The combination of TACE with lenvatinib plus ICIs showed excellent efficacy in the treatment of patients with BCLC-B stage HCC, and the safety profile was acceptable.
Authors
- Jing-Chang Liang (ORCID: https://orcid.org/0000-0002-5073-7620)
- Zhiming Zhang (ORCID: https://orcid.org/0000-0003-0389-0785)
- Yumei Zhang (ORCID: https://orcid.org/0000-0002-2871-3681)
- Xiang Nong (ORCID: https://orcid.org/0000-0002-5247-5134)
- Yu Yao (ORCID: https://orcid.org/0009-0002-7955-4817)
Institutions
- Guangxi Medical University (CN)
Publication Details
- Journal
- Journal of Gastrointestinal Oncology
- Published
- 2025-02-01
- DOI
- https://doi.org/10.21037/jgo-2025-33
- Citations
- 1
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.05